Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome
Trial Timeline
Dec 1, 2004 → Jan 1, 2006
NCT ID
NCT00144781About Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) is a approved stage product being developed by Sanofi for Mucopolysaccharidosis I. The current trial status is completed. This product is registered under clinical trial identifier NCT00144781. Target conditions include Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00144781 | Approved | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Odiparcil | Inventiva | Phase 2 | 47 |
| anakinra | Swedish Orphan Biovitrum | Phase 1/2 | 40 |
| laronidase | Sanofi | Approved | 84 |
| Laronidase | Sanofi | Approved | 84 |
| Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) | Sanofi | Phase 2 | 51 |
| Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza) | Sanofi | Phase 1/2 | 40 |
| Aldurazyme (Recombinant Human Alpha-L-Iduronidase) | Sanofi | Phase 3 | 76 |
| rhIDU (recombinant human-Alpha-L-Iduronidase) + Placebo | Sanofi | Phase 3 | 76 |
| Aldurazyme + Aldurazyme + placebo | Sanofi | Phase 3 | 76 |
| Laronidase | Sanofi | Approved | 84 |
| JR-141 | JCR Pharmaceuticals | Phase 2/3 | 64 |
| JR-441 + JR-441 + JR-441 | JCR Pharmaceuticals | Phase 1/2 | 40 |
| JR-446 | JCR Pharmaceuticals | Phase 1/2 | 40 |
| JR-171 | JCR Pharmaceuticals | Phase 1/2 | 40 |
| JR-141 | JCR Pharmaceuticals | Phase 2 | 51 |
| JR-141 + Idursulfase + JR-141 or Idursulfase | JCR Pharmaceuticals | Phase 3 | 76 |
| JR-141 | JCR Pharmaceuticals | Phase 3 | 76 |
| JR-171 (lepunafusp alfa) | JCR Pharmaceuticals | Phase 1/2 | 40 |
| JR-141 | JCR Pharmaceuticals | Phase 1/2 | 40 |
| JR-141 | JCR Pharmaceuticals | Phase 2/3 | 64 |